Evercore ISI raised the firm’s price target on Insmed to $42 from $32 and keeps an Outperform rating on the shares after having hosted talks with expert Dr. Ramzy Rimawi to reflect on the ARISE data released on Tuesday and get an opinion on usage of Arikyace in the front-line setting. The firm raised its price target as it raised its estimate on the odds of success for Arikayce in first-line to 60% from 30%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on INSM: